Mineralocorticoid Hypertension and Hypokalemia

Seminars in Nephrology

Volumn 26, Issue 6, 2006, Pages 434-440

  Khosla, Neenoo ^a   Hogan, Donn ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

hyperaldosteronism; hypertension; hypokalemia; mineralocorticoid

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FLUDROCORTISONE ACETATE; GLYCYRRHETINIC ACID; GLYCYRRHIZA EXTRACT; GLYCYRRHIZIC ACID; HYDROCORTISONE; MINERALOCORTICOID; POTASSIUM; PREDNISONE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ALDOSTERONE BLOOD LEVEL; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTICLE; CHROMOSOME; CHROMOSOME 8; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG USE; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; GLUCOCORTICOID REMEDIABLE HYPERTENSION; HUMAN; HYPERCALCIURIA; HYPERTENSION; HYPOKALEMIA; LIDDLE SYNDROME; METABOLIC ALKALOSIS; MINERALOCORTICOID HYPERTENSION; MONOGENIC DISORDER; MOON FACE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SCREENING TEST; SYMPTOM;

ALKALOSIS; BLOOD PRESSURE; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTENSION; HYPOKALEMIA; MINERALOCORTICOIDS; PROGNOSIS;

EID: 33846631969     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.10.004     Document Type: Article

References (64)

1. Hall J.E., Granger J.P., Smith Jr. M.J., et al. Role of renal hemodynamics and arterial pressure in aldosterone "escape". Hypertension 6 (1984) I183-I1192
2. White P.C., New M.I., and Dupont B. Congenital adrenal hyperplasia. N Engl J Med 316 (1987) 1519-1522
3. White P.C. Disorders of aldosterone biosynthesis and action. N Engl J Med 331 (1994) 250
4. Mitra A., and Batlle D. Aldosterone deficiency and resistance. acid-base and electrolyte disorders. In: Du B., and Hamm (Eds). A Companion to Brenner and Rector's the Kidney (2002), Saunders, Philadelphia 413-433
5. Batlle D., and Kurtzman N. Clinical disorders of aldosterone metabolism. Dis Mon 30 8 (1984) 1-55
6. Taymans S.E., Pack S., Pak E., et al. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab 83 (1998) 1033
7. Minuth W.W., Gilbert P., and Gross P. Appearance of specific proteins in the apical plasma membrane of cultured renal collecting duct principal cell epithelium after chronic administration of aldosterone and arginine vasopressin. Differentiation 38 (1988) 194
8. Verrey F. Early aldosterone action: Toward filling the gap between transcription and transport. Am J Physiol 277 (1999) F319
9. Masilamani S., Kim G.H., Mitchell C., et al. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest 104 (1999) R19
10. Shimkets R.A., Lifton R., and Canessa C.M. In vivo phosphorylation of the epithelial sodium channel. Proc Natl Acad Sci U S A 95 (1998) 3301
11. Hays S.R. Mineralocorticoid modulation of apical and basolateral membrane H+/OH-/HCO3- transport processes in rabbit inner stripe of outer medullary collecting duct. J Clin Invest 90 (1992) 180
12. Funder J.W. Mineralocorticoids, glucocorticoids, receptors and response elements. Science 259 (1993) 1132
13. Kenouch S., Coutry N., Farman N., et al. Multiple patterns of 11β-hydroxysteroid dehydrogenase catalytic activity along the mammalian nephron. Kidney Int 42 (1992) 56
14. Stewart P. Mineralocorticoid hypertension. Lancet 353 (1999) 1341-1347
15. Mulatero P., Dluhy R.G., Giacchetti G., et al. Diagnosis of primary aldosteronism: From screening to subtype differentiation. Trends Endocrinol Metab 16 (2005) 114-119
16. Mosso L., Carvajal C., Gonzalez A., et al. Primary hyperaldosteronism and hypertensive disease. Hypertension 42 (2003) 161-165
17. Hiramatsu K., Yamada T., Yukimura Y., et al. A screening test to identify aldosterone producing adenoma by measuring plasma renin activity: Results in hypertensive patients. Arch Intern Med 141 (1981) 1589-1593
18. Brown M., Cramp H., Zammit V., et al. Primary hyperaldosteronism: A missed diagnosis in essential hypertensives?. Aust N Z J Med 26 (1996) 533-538
19. Fardella C., Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 (2000) 1863-1867
20. Gallay B., Ahmad S., Xu L., et al. Screening for primary hyperaldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 37 (2001) 699-705
21. Gordon R., Ziesak M., Tunny T., et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 20 (1993) 296-298
22. Hamlet S., Tunny T., Woodland E., et al. Is aldosterone/renin ratio useful to screen a hypertensive population?. Clin Exp Pharmacol Physiol 12 (1985) 249-252
23. Kreze A., Okalova D., Vanuga P., et al. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vnitr Lek 45 (1999) 17-21
24. Kumar A., Lall S., Ammini A., et al. Screening of a population of young hypertensives for primary hyperaldosteronism. J Hum Hypertens 8 (1994) 731-732
25. Lazurova I., Schwartz P., Trejbal D., et al. Incidence of primary aldosteronism in hospitalized hypertensive patients. Bratisl Lek Listy 100 (1999) 200-203
26. Lim P., Dow E., Jung R., et al. Prevalence of primary aldosteronism in the tayside hypertension clinic population. J Hum Hypertens 14 (2000) 311-315
27. Loh K., Koay E., Khaw M., et al. Prevalence study on primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85 (2000) 2854-2859
28. Mosso L., Fardella C., Montero J., et al. High prevalence of undiagnosed primary aldosteronism among patients with essential hypertension. Rev Med Chil 127 (1999) 800-806
29. Rossi G., Rossi E., Pavan E., et al. Screening for primary aldosteronism with a logistic multivariate discriminate analysis. Clin Endocrinol 49 (1998) 713-723
30. Gordon R., Stowasser M., and Tunny T. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 (1994) 315-318
31. Lim P., Rodgers P., Cardale K., et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353 (1999) 40
32. Montori V., and Young W. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31 (2002) 619-632
33. Weinberger M., and Fineberg N. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 153 (1993) 2125-2129
34. Young W. Primary aldosteronism. A common and curable form of hypertension. Cardiol Rev 7 (1999) 207-214
35. Tiu T., Choi C., Shek C., et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 90 (2005) 72-78
36. Lyons D., Kem D., Brown R., et al. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 57 (1983) 892-896
37. Nadler J., Hsueh W., and Horton R. Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60 (1985) 896-899
38. Gleason P.E., Weinberger M.H., Pratt J.H., et al. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: Unilateral adenoma versus bilateral micronodular hyperplasia. J Urol 150 (1993) 1365
39. Radin D.R., Manoogian C., and Nadler J.L. Diagnosis of primary hyperaldosteronism: Importance of correlating CT findings with endocrinologic studies. AJR Am J Roentgenol 158 (1992) 553
40. Doppman J.L., McGill J.R., Miller D.L., et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: Reliability of CT. Radiology 184 (1992) 677
41. Young W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 136 (2004) 1227
42. Lumachi F., Ermani M., Basso S.M., et al. Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: Multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 71 (2005) 864-869
43. Sawka A.M., Young W.F., Thompson G.B., et al. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery. Ann Intern Med 135 (2001) 258-261
44. Minowada S., Fujimura T., Takahashi N., et al. Computed tomography-guided percutaneous acetic acid injection therapy for functioning adrenocortical adenoma. J Clin Endocrinol Metab 88 (2003) 5814
45. Kawasaki T., Omae T., Tanaka K., et al. Remission or recurrent hyperaldosteronism resulting from subtotal adrenalectomy of adenomatous hyperplastic adrenal glands. J Clin Endocrinol Metab 33 (1971) 474-480
46. Ghose R.P., Hall P.M., and Bravo E.L. Medical management of aldosterone-producing adenomas. Ann Intern Med 131 (1999) 105-108
47. Rossi G.P., Sacchetto A., Pavan E., et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95 (1997) 1471-1478
48. Rich G.M., Ulick S., Cook S., et al. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 116 (1992) 813
49. Lifton R.P., Dluhy R.G., Powers M., et al. A chimeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355 (1992) 262
50. Pascoe L., Curnow K.M., Slutsker L., et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 89 (1992) 8327-8331
51. McMahon G.T., and Dluhy R.G. Glucocorticoid-remediable aldosteronism. Cardiol Rev 12 (2004) 44-48
52. Dluhy R.G., and Lifton R.P. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 60 (1995) 48-51
53. Litchfield W.R., Anderson B.F., Weiss R.J., et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31 (1998) 445-450
54. Stewart P.M., Corrie J.E., Shackleton C.H., et al. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82 (1988) 340-349
55. Quinkler M., and Stewart P.M. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 88 (2003) 2384-2392
56. Dave-Sharma S., Wilson R.C., Harbison M.D., et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 83 (1998) 2244-2254
57. Wilson R.C., Krozowski Z.S., Li K., et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80 (1995) 2263-2266
58. Mariniello B., Ronconi V., Sardu C., et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens 18 (2005) 1091-1098
59. Palermo M., Cossu M., and Shackelton C.H.L. Cure for apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 329 (1998) 1787-1788
60. Farese Jr. R.V., Biglieri E.G., Gomez F.R., et al. Licorice- induced hypermineralocorticoidism. N Engl J Med 325 (1991) 1223-1227
61. Whorwood C.B., Sheppard M.C., and Stewart P. Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology 132 (1993) 2287-2292
62. Ulick S., Wang J.Z., Blumenfeld J.D., et al. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 74 (1992) 963-967
63. Williams T.A., Mulatero P., Filigheddu F., et al. Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney Int 67 (2005) 63-67
64. Mariniello B., Ronconi V., Sardu C., et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens 18 (2005) 1091-1098